• LAST PRICE
    0.9996
  • TODAY'S CHANGE (%)
    Trending Down-0.0504 (-4.8000%)
  • Bid / Lots
    0.9900/ 3
  • Ask / Lots
    0.9996/ 10
  • Open / Previous Close
    1.0600 / 1.0500
  • Day Range
    Low 0.9757
    High 1.0659
  • 52 Week Range
    Low 0.9000
    High 2.1200
  • Volume
    413,728
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 1.05
TimeVolumeCLSD
09:32 ET56551.04
09:33 ET1001.0659
09:42 ET19711.0504
09:44 ET1001.05
09:46 ET213501.04
09:50 ET3001.05
09:51 ET15001.04
09:53 ET2501.0406
09:55 ET8501.040643
09:57 ET20001.045
10:02 ET15461.05
10:04 ET8981.0404
10:06 ET7001.0428
10:08 ET1001.04
10:13 ET10001.0301
10:18 ET2001.035
10:20 ET218021.02
10:26 ET27591.02
10:27 ET232701.01
10:31 ET30001.015
10:33 ET5001.0195
10:36 ET27001.02
10:38 ET4091.02
10:40 ET67141.0104
10:45 ET10001.0192
10:47 ET98701.02
10:49 ET14001.0174
10:51 ET10001.0196
10:54 ET10001.01
10:56 ET1011.0197
10:58 ET2001.0104
11:00 ET10001.02
11:02 ET2001.0105
11:03 ET6001.0195
11:05 ET113281.0128
11:07 ET67891.01
11:12 ET15001.0056
11:16 ET21991.0059
11:20 ET118001
11:21 ET100001.0059
11:25 ET1001
11:30 ET11001.0009
11:32 ET11001.005
11:34 ET2001
11:36 ET1001
11:38 ET101001
11:39 ET1001
11:41 ET66001.005
11:43 ET9601
11:48 ET211001.01
11:50 ET20001.0097
11:52 ET19981.01
11:57 ET3851.0107
11:59 ET99931
12:06 ET17741.01
12:08 ET128601.005
12:10 ET3001.005
12:15 ET1001.005
12:17 ET9001
12:19 ET1981
12:21 ET2001
12:28 ET2001
12:30 ET1001
12:32 ET50001.005
12:33 ET7001.0059
12:35 ET2001.0099
12:37 ET1001
12:39 ET1001.005
12:42 ET2001
12:44 ET5001.0092
12:46 ET26001.0095
12:48 ET8001.005
12:50 ET1001
12:53 ET3001.01
12:55 ET47601.005
12:57 ET3871.005
01:00 ET1001.005
01:02 ET1001.005
01:04 ET3001.005
01:06 ET1001.005
01:08 ET1001
01:11 ET1001
01:20 ET11001.009
01:22 ET1001
01:24 ET1001
01:26 ET2001
01:29 ET9001.005
01:31 ET1001
01:33 ET2001
01:36 ET4001
01:38 ET827660.995
01:40 ET3000.99495
01:42 ET77000.99
01:44 ET1000.989
01:45 ET33000.98
01:47 ET2000.9757
01:49 ET1000.979
01:51 ET26000.98
01:54 ET18500.989951
01:56 ET27000.98995
01:58 ET4000.9899
02:00 ET4000.98995
02:02 ET25220.99
02:03 ET9000.9997
02:05 ET2000.99
02:07 ET1000.990449
02:09 ET1000.99
02:12 ET10750.994749
02:14 ET6500.99
02:16 ET3750.994749
02:18 ET2000.9947
02:20 ET83000.99
02:21 ET9500.9904
02:23 ET2000.9904
02:25 ET3000.99035
02:32 ET1000.989
02:34 ET1150.989
02:36 ET19000.9998
02:38 ET2000.9949
02:39 ET1000.99
02:41 ET51000.99
02:43 ET1500.994899
03:19 ET1000.9949
03:21 ET1000.9998
03:28 ET1000.99
03:30 ET4200.9905
03:32 ET1220.9901
03:33 ET11000.9944
03:35 ET5000.9901
03:37 ET6880.99
03:39 ET4000.9996
03:42 ET2560.9905
03:44 ET5000.9996
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCLSD
Clearside Biomedical Inc
78.5M
-2.2x
---
United StatesATRA
Atara Biotherapeutics Inc
72.3M
-0.5x
---
United StatesCRVO
CervoMed Inc
90.1M
-22.3x
---
United StatesIKNA
Ikena Oncology Inc
93.4M
-1.4x
---
United StatesAFMD
Affimed NV
55.6M
-0.6x
---
United StatesCUE
Cue Biopharma Inc
90.3M
-1.3x
---
As of 2024-11-15

Company Information

Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Contact Information

Headquarters
900 North Point Parkway, Suite 200ALPHARETTA, GA, United States 30005
Phone
678-270-3631
Fax
678-270-4033

Executives

Independent Chairman of the Board
Anthony Gibney
President, Chief Executive Officer, Director
George Lasezkay
Chief Financial Officer
Charles Deignan
Chief Medical Officer
Victor Chong
Independent Director
Richard Croarkin

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$78.5M
Revenue (TTM)
$7.7M
Shares Outstanding
74.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.31
EPS
$-0.45
Book Value
$-0.25
P/E Ratio
-2.2x
Price/Sales (TTM)
10.2
Price/Cash Flow (TTM)
---
Operating Margin
-300.96%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.